Business · 02/10/2015Updated: 10/17/2026 · 1 min read
Reopening of Comment Period for In Vitro Bioequivalence Pathways for Veterinary Drug Products
Summary
The Food and Drug Administration (FDA) is reopening the comment period for discussing alternative in vitro bioequivalence pathways to ensure the in vivo bioequivalence of non-systemically absorbed drug products for animals, originally published on March 18, 2015 (80 FR 14146).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →